PureTech Health plc (NASDAQ:PRTC – Get Free Report) traded down 6.3% on Thursday . The stock traded as low as $17.04 and last traded at $17.55. 6,778 shares traded hands during trading, an increase of 273% from the average session volume of 1,816 shares. The stock had previously closed at $18.73.
PureTech Health Stock Down 6.3 %
The firm has a fifty day moving average price of $20.91 and a 200 day moving average price of $21.35.
About PureTech Health
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
See Also
- Five stocks we like better than PureTech Health
- Using the MarketBeat Stock Split Calculator
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- How to trade using analyst ratings
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- What is a Secondary Public Offering? What Investors Need to Know
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
